Macrogenics (MGNX) Long-Term Deferred Tax (2014)

Macrogenics' (MGNX) quarterly Long-Term Deferred Tax came in at $1.6 million in Q4 2014.

Macrogenics (MGNX) Long-Term Deferred Tax (2014) Analysis & Trends

Macrogenics (MGNX) has 1 years of Long-Term Deferred Tax data on file, last reported at $1.6 million in Q4 2014.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $1.6 million in Q4 2014; TTM through Dec 2014 was $1.6 million, a N/A change from a year earlier, with the FY2014 full-year figure at $1.6 million, changed N/A from the prior year.
Long-Term Deferred Tax for Q4 2014 stood at $1.6 million.
Over the last five years, Long-Term Deferred Tax for MGNX reached as high as $1.6 million in Q4 2014 and fell as low as $1.6 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Macrogenics	254.43 Mn	187.92 Mn	-

Download Data

Date	Value
Dec 31, 2014	1.60 Mn